Theralase Technologies (TLT) Q1 2025 earnings summary

Executive summary

• Enrollment in the pivotal bladder cancer study is expected to complete by summer 2025, enabling a new drug application submission to Health Canada and the FDA by Q4 2026, with potential marketing approval in early 2027 if priority review is granted.

• The company is expanding its pipeline to nine additional oncology and virology indications, with GLP toxicology studies expected to finish by end of 2025 and adaptive phase 1/2 clinical studies to begin in Q1 2026.

• Strategic initiatives include a potential U.S. uplist, concurrent U.S. institutional financing, and separation of drug and device division reporting and funding.

• The Drug Division remains pre-commercial, with no revenue, while the Device Division saw significant sales declines in all geographies.

• Material uncertainties exist regarding the company’s ability to continue as a going concern, with negative working capital and ongoing need for additional financing.

Financial highlights

• Q1 2025 revenue was $91,190 (CAD 91,000), down 48% year-over-year, reflecting focus on clinical study investment and weak device sales.

• Gross margin was 15% of revenue, impacted by reduced sales and fixed overhead.

• Net loss for Q1 2025 was $1,471,250 (CAD 1.47 million), including $256,000 in non-cash charges, up from $1,266,711 in Q1 2024.

• Cash and cash equivalents at March 31, 2025 were $131,764, with negative working capital of -$299,942.

• Shareholders’ equity declined to $1,090,195 from $2,067,448 at December 31, 2024.

Outlook and guidance

• Management expects to complete enrollment in the Phase II NMIBC study by summer 2025, with top-line data for 75 patients in December 2025 and all 90 patients by September 2026.

• Plans to submit a New Drug Application to Health Canada and FDA in Q4 2026, with a decision expected in Q1 2027.

• Estimated $8–10 million required to complete study two, follow-up, data lock, and regulatory submissions over the next 18 months.

• Exploring U.S. institutional raise and public listing to broaden investor base and fund pipeline expansion.

• The company is actively seeking new financing and intends to complete a financing round in Q2 2025.